G2 Intelligence is excited to announce that our annual Lab Institute event will return in November 2022 as a free virtual event. Running Nov. 8-9, the event will offer a variety of presentations aimed at helping clinical, medical, and pathology labs succeed in today’s challenging environment and beyond.
In addition to the prison sentence for the x-ray-related fraud scheme, the company president must also pay nearly $2 million in restitution.
A significant new court ruling from a Minnesota federal court draws a line on how far labs can go when insurers short-change them.
Recent study provides new details on how COVID-19 impacted cancer deaths in the US early in the pandemic and which groups were most affected.
The developer of NGS-based companion diagnostics targets the growing neurology biomarker market.
A recent study shows pharmacogenetic testing can help caregivers make better decisions when prescribing antidepressants.
The new CAP guidance addresses use of immune checkpoint inhibitors for evaluating and treating patients with specific cancers.
What the equity rule is, who it affects, and how to comply.
Despite lessons learned from COVID-19 testing, HHS and FDA plan for monkeypox testing remains flawed.
While new FDA clearances of blood-based early detection tests for Alzheimer’s represent significant progress, limitations remain.
Pathologist Rajesh C. Dash, MD, discusses the state of AI and digital pathology, as well as challenges and possible solutions.
Two lab staffing experts weigh in on current trends and what labs need to do to attract and retain talent in today’s environment.
A roundup of key mergers, acquisitions, and strategic asset purchases in the healthcare industry in September.
The Hilden, Germany-based company is extending its genetic testing profile beyond oncology to neurology biomarkers.